Effects of RAS inhibitors on all-site cancers and mortality in the Hong Kong diabetes surveillance database (2002-2019)

BACKGROUND: Cancer is replacing cardiovascular-disease as a leading cause of death in type 2 diabetes (T2D). The association of RAS-inhibitors (RASi) and cancer, including differences between angiotensin-converting-enzyme-inhibitor (ACEi) and angiotensin-receptor-blocker (ARBs) as well as their asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Aimin, Wu, Hongjiang, Lau, Eric S.H., Shi, Mai, Fan, Baoqi, Kong, Alice Pik-Shan, Ma, Ronald Ching-Wan, Luk, Andrea On-Yan, Chan, Juliana Chung-Ngor, Chow, Elaine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399959/
https://www.ncbi.nlm.nih.gov/pubmed/35970023
http://dx.doi.org/10.1016/j.ebiom.2022.104219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399959/
https://www.ncbi.nlm.nih.gov/pubmed/35970023
http://dx.doi.org/10.1016/j.ebiom.2022.104219

Ejemplares similares